Patents by Inventor Clive R. Wood

Clive R. Wood has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9051377
    Abstract: Proteins that bind to matrix metalloproteinase 14 and methods of using such proteins are described.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: June 9, 2015
    Assignee: Dyax Corp.
    Inventors: Laetitia Devy, Henk Pieters, Robert C. Ladner, Rene Hoet, Daniel T. Dransfield, Clive R. Wood, Maria Henderikx
  • Publication number: 20130244890
    Abstract: Provided are compositions, methods and kits for quantifying the expression and/or activity of MMP-14 and other biomarkers of cancer, which may be used diagnostically and prognostically, e.g., in patient stratification and evaluation of appropriate therapeutic regimens.
    Type: Application
    Filed: April 24, 2012
    Publication date: September 19, 2013
    Applicant: DYAX CORP.
    Inventors: Clive R. Wood, Daniel T. Dransfield, Laetitia Devy
  • Patent number: 8501181
    Abstract: Provided are methods and compositions for using MMP-14 or MMP-9 binding proteins alone or in combination with other therapeutic agents to treat osteolytic disorders such as osteotropic cancer and osteoporosis.
    Type: Grant
    Filed: December 28, 2011
    Date of Patent: August 6, 2013
    Assignee: Dyax Corp.
    Inventors: Clive R. Wood, Daniel T. Dransfield, Laetitia Devy
  • Publication number: 20120141473
    Abstract: Provided are methods and compositions for using MMP-14 or MMP-9 binding proteins alone or in combination with other therapeutic agents to treat osteolytic disorders such as osteotropic cancer and osteoporosis.
    Type: Application
    Filed: December 28, 2011
    Publication date: June 7, 2012
    Applicant: DYAX CORP.
    Inventors: Clive R. Wood, Daniel T. Dransfield, Laetitia Devy
  • Patent number: 8183008
    Abstract: Provided are compositions, methods and kits for quantifying the expression and/or activity of MMP-14 and other biomarkers of cancer, which may be used diagnostically and prognostically, e.g., in patient stratification and evaluation of appropriate therapeutic regimens.
    Type: Grant
    Filed: December 17, 2008
    Date of Patent: May 22, 2012
    Assignee: Dyax Corp.
    Inventors: Clive R. Wood, Daniel T. Dransfield, Laetitia Devy
  • Publication number: 20120107231
    Abstract: Proteins that bind to matrix metalloproteinase 14 and methods of using such proteins are described.
    Type: Application
    Filed: December 22, 2011
    Publication date: May 3, 2012
    Applicant: DYAX CORP.
    Inventors: Laetitia Devy, Henk Pieters, Robert C. Ladner, Rene Hoet, Daniel T. Dransfield, Clive R. Wood, Maria Henderikx
  • Patent number: 8147836
    Abstract: Provided are methods and compositions for using MMP-14 or MMP-9 binding proteins alone or in combination with other therapeutic agents to treat osteolytic disorders such as osteotropic cancer and osteoporosis.
    Type: Grant
    Filed: December 17, 2008
    Date of Patent: April 3, 2012
    Assignee: Dyax Corp.
    Inventors: Clive R. Wood, Daniel T. Dransfield, Laetitia Devy
  • Patent number: 8106168
    Abstract: Proteins that bind to matrix metalloproteinase 14 and methods of using such proteins are described.
    Type: Grant
    Filed: May 7, 2010
    Date of Patent: January 31, 2012
    Assignee: Dyax Corp.
    Inventors: Laetitia Devy, Henk Pieters, Robert C. Ladner, Rene Hoet, Daniel T. Dransfield, Clive R. Wood, Maria Henderikx
  • Patent number: 8088905
    Abstract: This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders.
    Type: Grant
    Filed: March 16, 2009
    Date of Patent: January 3, 2012
    Assignees: Wyeth, MedImmune Limited
    Inventors: Mary Collins, Clive R. Wood, Beatriz M. Carreno, Deborah Luxenberg, Jason Jussif, Laura L. Carter, Frances K. Bennett, Viia Valge-Archer, John Andrews, Caroline Russell
  • Publication number: 20110262396
    Abstract: Provided are methods and compositions for using protease binding proteins in combination with other therapeutic agents to treat inflammatory disorders such as rheumatoid arthritis, psoriasis, multiple sclerosis, systemic sclerosis, asthma, chronic obstructive pulmonary disease, inflammatory bowel disease (e.g., Crohn's and ulcerative colitis). The use of the protease binding protein allows a lower dose of the other therapeutic agents to be used in the methods and compositions, such that side effects of the other therapeutic agents are reduced or removed.
    Type: Application
    Filed: October 22, 2009
    Publication date: October 27, 2011
    Applicant: DYAX CORP.
    Inventor: Clive R. Wood
  • Publication number: 20110059105
    Abstract: Tie1 and Tie2 are receptor tyrosine kinase proteins that include a transmembrane domain. Tie1 and Tie2 are present on endothelial cells. This disclosure describes agents, such as antibodies, that bind to Tie1, Tie2, and Ang, including ones that inhibit endothelial cell activity.
    Type: Application
    Filed: June 28, 2010
    Publication date: March 10, 2011
    Applicant: DYAX CORP.
    Inventors: Clive R. Wood, Daniel T. Dransfield, Henk Pieters, Rene Hoet, Simon E. Hufton
  • Patent number: 7871610
    Abstract: Tie1 and Tie2 are receptor tyrosine kinase proteins that include a transmembrane domain. Tie1 and Tie2 are present on endothelial cells. This disclosure describes agents, such as antibodies, that bind to Tie1, Tie2, and Ang, including ones that inhibit endothelial cell activity.
    Type: Grant
    Filed: February 2, 2005
    Date of Patent: January 18, 2011
    Assignee: Dyax Corp.
    Inventors: Clive R. Wood, Daniel T. Dransfield, Henk Pieters, Rene Hoet, Simon E. Hufton
  • Publication number: 20100266490
    Abstract: Proteins that bind to matrix metalloproteinase 14 and methods of using such proteins are described.
    Type: Application
    Filed: May 7, 2010
    Publication date: October 21, 2010
    Applicant: DYAX CORP.
    Inventors: Laetitia Devy, Henk Pieters, Robert C. Ladner, Rene Hoet, Daniel T. Dransfield, Clive R. Wood, Maria Henderikx
  • Publication number: 20100196361
    Abstract: Tie1 and Tie2 are receptor tyrosine kinase proteins that include a transmembrane domain. Tie1 and Tie2 are present on endothelial cells. This disclosure describes agents, such as antibodies, that bind to Tie1, Tie2, and Ang, including ones that inhibit endothelial cell activity and angiogenesis. The agents can be used to treat angiogenesis-associated disorders.
    Type: Application
    Filed: December 17, 2008
    Publication date: August 5, 2010
    Applicant: DYAX CORP.
    Inventors: Clive R. Wood, Daniel T. Dransfield, Henk Pieters, Rene Hoet, Simon E. Hufton
  • Patent number: 7745587
    Abstract: Proteins that bind to matrix metalloproteinase 14 and methods of using such proteins are described.
    Type: Grant
    Filed: December 29, 2006
    Date of Patent: June 29, 2010
    Assignee: Dyax Corp.
    Inventors: Laetitia Devy, Henk Pieters, Robert C. Ladner, Rene Hoet, Daniel T. Dransfield, Clive R. Wood, Maria Henderikx
  • Patent number: 7709214
    Abstract: The invention provides isolated nucleic acids molecules, designated PD-L2 nucleic acid molecules, which encode novel B7-related molecules which are ligands for PD-1. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PD-L2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PD-L2 gene has been introduced or disrupted. The invention further provides isolated PD-L2 polypeptides, fusion proteins, antigenic peptides and anti-PD-L2 antibodies. The invention still further provides methods for promoting or inhibiting the interaction between PD-L2 and PD-1. Diagnostic and treatment methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: June 20, 2007
    Date of Patent: May 4, 2010
    Assignees: Dana-Farber Cancer Institute, Inc., Genetics Institute, LLC
    Inventors: Gordon J. Freeman, Irene Chernova, Tatyana Chernova, Nelly Malenkovich, Clive R. Wood
  • Patent number: 7700301
    Abstract: Disclosed are screening assays for identifying compounds which modulate the activity of, or signaling via, B7-4, or PD-1, especially which modulate the binding of B7-4 or PD-1 to a target molecule.
    Type: Grant
    Filed: September 11, 2006
    Date of Patent: April 20, 2010
    Assignees: Dana-Farber Cancer Institute Inc., Wyeth
    Inventors: Clive R. Wood, Gordon J. Freeman, Divya Chaudhary
  • Publication number: 20100028330
    Abstract: This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders.
    Type: Application
    Filed: March 16, 2009
    Publication date: February 4, 2010
    Applicants: Medimmune Limited, Wyeth
    Inventors: Mary Collins, Clive R. Wood, Beatriz M. Carreno, Deborah Luxenberg, Jason Jussif, Laura L. Carter, Frances K. Bennett, Viia-Valge Archer, John Andrews, Caroline Russell
  • Patent number: 7638492
    Abstract: The invention identifies PD-1 as a receptor for B7-4. B7-4 can inhibit immune cell activation upon binding to an inhibitory receptor on an immune cell. Accordingly, the invention provides agents for modulating PD-1, B7-4, and the interaction between B7-4 and PD-1 in order to modulate a costimulatory or an inhibitory signal in a immune cell resulting in modulation of the immune response.
    Type: Grant
    Filed: August 31, 2006
    Date of Patent: December 29, 2009
    Assignees: Dana-Farber Cancer Institute, Inc., Genetics Institute, LLC
    Inventors: Clive R. Wood, Gordon J. Freeman
  • Publication number: 20090214520
    Abstract: The invention relates to methods of treating a disease or condition, wherein expression or activity of soluble CLCA1 is up-regulated, by administering inhibitors of soluble CLCA1. The invention also relates to methods of isolating soluble CLCA1 from a bodily fluid.
    Type: Application
    Filed: August 21, 2008
    Publication date: August 27, 2009
    Inventors: Andrew J. Long, Clive R. Wood, Michael Bowman, Samuel J. Goldman, Joseph P. Sypek